Description: Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Home Page: www.insmed.com
0JAV Technical Analysis
700 US Highway 202/206
Bridgewater,
NJ
08807
United States
Phone:
908 977 9900
Officers
| Name | Title |
|---|---|
| Mr. William H. Lewis J.D., M.B.A. | President, CEO & Chairman |
| Ms. Sara M. Bonstein M.B.A. | Chief Financial Officer |
| Mr. Roger Adsett M.B.A. | Chief Operating Officer |
| Mr. John Drayton Wise M.B.A. | Chief Commercial Officer |
| Dr. Martina Flammer M.B.A., M.D. | Chief Medical Officer |
| Mr. Brian K. Kaspar Ph.D. | Chief Scientific Officer |
| Ms. Eleanor Barisser | Associate Director of Investor Relations |
| Mr. Michael Alexander Smith J.D. | Chief Legal Officer & Corporate Secretary |
| Mandy Fahey | Executive Director of Corporate Communications |
| Ms. S. Nicole Schaeffer M.B.A. | Chief People Strategy Officer |
Exchange: LSE
Country: GB : United Kingdom of Great Britain and Northern Ireland
Currency: US Dollar ($)
| GIC Sector: | Industrials |
|---|---|
| GIC Group: | Commercial & Professional Services |
| GIC Industry: | Commercial Services & Supplies |
| GIC Sub-Industry: | Environmental & Facilities Services |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 19.101 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 912 |